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Abstract
Purpose. Within the community, 10% of acquired pneumonia is caused by Chlamydia pneumoniae. N-acetyl-cysteine (NAC) is
one of the most commonly used mucolytics in respiratory diseases, but its effect on C. pneumoniae infection has not yet been
investigated. In this study, our aim was to investigate whether NAC influences the replication of C. pneumoniae. After
determining that NAC does have an effect on C. pneumoniae replication, the effect of an alternative drug called Ambroxol (Ax)
was investigated.
Methodology. The in vitro effect of NAC and Ax was studied on C. pneumoniae-infected A549 and McCoy cells. Furthermore,
the influence of NAC and Ax was examined in mice infected intranasally with C. pneumoniae.
Results. NAC treatment resulted in approximately sixfold more efficient C. pneumoniae growth in tissue culture compared to
the untreated control cells, and this effect was shown to be based on the increased binding of the bacterium to the host
cells. The C. pneumoniae-infected mice to which NAC was given had prolonged and more severe infections than the control
mice. Ax decreased C. pneumoniae replication in vitro, which was partially associated with the increased expression of
indolamine 2,3-dioxygenase. In animals, using the adapted usual human dose, Ax did not alter the number of recoverable
C. pneumoniae.
Conclusion. Based on our results, it might be recommended that a mucolytic agent other than NAC, such as Ax, be used in
respiratory diseases suspected to be caused by C. pneumoniae.
INTRODUCTION
N-acetyl-cysteine (NAC) is a commonly used agent in the
healthcare profession. It has multiple therapeutic uses in
psychiatry and is useful in the case of an acetaminophen
overdose. Moreover, NAC is used as a mucolytic agent in
respiratory diseases, where its free thiol group breaks down
the disulphide bonds in mucus, thereby decreasing its vis-
cosity. NAC is mostly taken per os, except when it is taken
to combat acetaminophen intoxication [1]. Ambroxol (Ax)
is another mucolytic and expectorant drug that is used to
treat different respiratory diseases. In addition to the effects
of Ax on mucus regulation and its local anaesthetic effects, a
wide range of pharmacological anti-inflammatory proper-
ties of Ax have been described in vitro and in vivo [2, 3].
Chlamydia pneumoniae, belonging to the family Chlamy-
diaceae, is a Gram-negative obligate intracellular bacterium.
It is a common cause of acute respiratory infection,
including community-acquired pneumonia, sinusitis, phar-
yngitis, bronchitis and exacerbations of chronic bronchitis.
C. pneumoniae is responsible for approximately 10% of
pneumonia cases [4]. The infectivity of Chlamydia species
depends on the reduced state of a cysteine-rich protein [5].
There is a cysteine-rich, strongly disulphide cross-linked
protein of the family Chlamydiaceae that is called OmcB,
and this is indispensible for binding [6]. C. pneumoniae and
Chlamydia trachomatis carry OmcB protein in their outer
membrane, where the reduction of its disulphide bonds can
be achieved by glutathione (GSH) [7] and by the host cell’s
protein disulphide isomerase [5]. The influence of NAC, a
potent reducing agent, on C. pneumoniae replication has
not yet been investigated. On the basis of our hypothesis,
the reduction of OmcB (which has the highest disulphide
content among the structural proteins in C. pneumoniae) by
NAC can increase binding and consequently increase the
replication of C. pneumoniae. In this study, we found that
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NAC promotes C. pneumoniae growth in vitro and aggra-
vates the severity of pneumonia in mice.
METHODS
Propagation of C. pneumoniae
In our experiments, the CWL029 strain of C. pneumoniae
from the ATCC (Manassas, VA, USA) was used. C. pneu-
moniae was propagated in HEp-2 cells (ATCC), as
described previously [8, 9]. The titre of the infectious ele-
mentary bodies (EBs) was determined by indirect immuno-
fluorescence assay. Serial dilutions of the EB preparation
were inoculated onto McCoy cells (ECACC, London UK),
and after being cultured for 48 h, the cells were fixed with
acetone and stained with a monoclonal anti-Chlamydia
lipopolysaccharide antibody (AbD Serotec, Oxford, UK)
and FITC-labelled anti-mouse IgG (Sigma, St Louis, MO,
USA). The number of C. pneumoniae inclusions was
counted under a UV microscope, and the titre was
expressed as inclusion-forming units/ml (i.f.u. ml 1).
In vitro effect of NAC and Ax
McCoy and A549 (ATCC) cultures were grown in 24-well
tissue culture plates containing a 13mm cover glass in mini-
mum essential medium Eagle with Earle’s salts (Sigma), sup-
plemented with 10% vol/vol foetal calf serum, 0.5% wt/vol
glucose, 0.3mg of L-glutamine ml 1, 4mMHEPES and 25 µg
of gentamycin ml 1. Five parallel wells of semi-confluent
cultures were infected with 2103well 1 C. pneumoniae or
treated simultaneously with NAC (0.01–10mgml 1) or Ax
(0.002–0.05mgml 1) at the time of infection. Separate cells
were infected with C. pneumoniae pretreated (1 h) with dif-
ferent concentrations of NAC. Subsequently, C. pneumoniae
EBs were pretreated with NAC or Ax by continuous shaking
in the presence of NAC (0.1mgml 1) or Ax (0.05mgml 1)
at room temperature, and after 1 h these drugs were washed
out using a culture medium and centrifugation at 13 800 g
for 15min (Heraus Fresco 17) or left unwashed. NAC- or
Ax-treated C. pneumoniae or non-treated C. pneumoniae
were inoculated onto cells on cover glasses in 24-well plates
and centrifuged at 800 g for 1 h. After incubation for 48 h,
the cells on the cover glasses were fixed with acetone and
stained as described above in the ‘Propagation of C. pneumo-
niae’ section to visualize the inclusions of C. pneumoniae. In
order to detect the effect of NAC or Ax on the attachment of
chlamydial EBs to host cells, McCoy or A549 cells were
infected with NAC- or Ax-treated C. pneumoniae EBs and
after a 1 h incubation period and centrifugation the cells
were washed and fixed and the bound EBs were stained by
indirect immunofluorescence, as described above.
Fluorescence signals were analysed via Olympus UV
microscopy. The immunofluorescence of non-infected or
C. pneumoniae-infected cells, or cells infected with drug-
treated C. pneumoniae was analysed quantitatively by
ImageQuantTL 8.1 software as follows: 6–6 equally sized
circular areas covering the cells were randomly selected on
each image, and then the background signals of the selected
areas were eliminated by a threshold set-up and the fluores-
cence intensity/pixel values of the randomly selected cells
were quantified.
Mice and infection conditions
Pathogen-free 6-week-old female BALB/c mice were
obtained from Charles River Laboratories (Hungary). The
mice were maintained under standard husbandry condi-
tions at the animal facility of the Department of Medical
Microbiology and Immunobiology, University of Szeged,
and were provided with food and water ad libitum. Before
infection, the mice were mildly sedated with an intraperito-
neal injection of 200 µl of sodium pentobarbital (7.5mg
ml 1). They were then infected intranasally with 2105 i.f.u.
C. pneumoniae in 20 µl sucrose/phosphate/glutamic acid
(SPG) buffer, and from the second day post-infection they
were treated with 0.2mg NAC (Sigma) in a volume of 50 µl
drinking water per os daily. Mice were anaesthetized and
sacrificed 7 days, or in another experiment 20 days, after the
infection. Blood was then taken by cardiac puncture. In a
separate study, C. pneumoniae-infected mice were treated in
a similar way as above with 25 µg Ax (Sigma) and sacrificed
7 days after infection. The control mice received the same
amount of tap water by oral administration using a Gilson
pipette to mimic the stress of the watering process. After
euthanization, the lungs of the mice were removed and
homogenized with acid-purified sea sand (Fluka Chemie
AG, Buchs, Switzerland). The homogenized lungs were sus-
pended in 1ml of SPG for the detection of viable C. pneu-
moniae. The experiments were approved by the Animal
Welfare Committee of the University of Szeged and they
conformed to Directive 2010/63/EU of the European
Parliament.
The culturing of C. pneumoniae from the lungs of
mice
After two freeze-thaw cycles, the homogenized lungs from
individual mice were centrifuged (10min, 400 g) and serial
dilutions of the supernatants were inoculated onto McCoy
cell monolayers. These samples were then centrifuged (1 h,
800 g), and after a 48 h culture the cells were fixed with ace-
tone and stained as described above in the ‘Propagation of
C. pneumoniae’ section to visualize the inclusions of
C. pneumoniae.
Total RNA extraction and cDNA synthesis
One-day-old semi-confluent McCoy cells in six-well plates
were infected with C. pneumoniae using a multiplicity of
infection (m.o.i.) of 4. The cells were then left untreated or
NAC (0.1mgml 1) or Ax (0.05mgml 1) were added to the
medium. Total RNA was extracted after a 1-day incubation
from three parallel wells of each condition with Tri Reagent
according to the manufacturer’s protocol (Sigma). RNA
concentrations were measured at 260 nm via a NanoDrop
spectrophotometer (Thermo Scientific, Waltham, MA,
USA). The purity of the RNA samples was given as the ratio
of the RNA absorbance at 260 and 280 nm, which was
higher than 2 in each sample. Afterwards, 1 µg of total RNA
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was reverse-transcribed using Maxima Reverse Transcrip-
tase according to the manufacturer’s protocol with random
hexamer priming (Thermo Fisher Scientific, Inc. Waltham,
MA, USA).
Quantitative PCR (qPCR) of the indolamine 2,3-
dioxygenase 1,2 (IDO1,2)
qPCR was performed in a Bio-Rad CFX96 real-time system
by using a SsoFast EvaGreen qPCR Supermix (Bio-Rad,
Hercules, CA, USA) master mix and the murine-specific
primer pairs IDO1 : 5¢-GCTTCTTCCTCGTCTCTCTA
TTG-3¢, 5¢-TCTCCAGACTGGTAGCTATGT-3¢; IDO2 : 5¢-
CCTGGACTGCAGATTCCTAAAG-3¢, 5¢-CCAAGTTCC
TGGATACCTCAAC-3¢; beta-actin: 5¢-TGGAATCCTG
TGGCATCCATGAAAC-3¢, 5¢-TAAAACGCAGCTCAG
TAACAGTCCG-3¢. All of the primers were designed using
PrimerQuest Tool (IDT) software and synthesized by Inte-
grated DNA Technologies, Inc. (Montreal, Quebec, Can-
ada). To check the amplification specificity, the qPCR was
followed by a melting curve analysis. Threshold cycles (Ct)
were calculated for the IDO1, IDO2 and beta-actin genes,
and the relative gene expressions were calculated by the
DDCt method. Student’s t-test was used to compare the sta-
tistical differences of DCt values between the infected and
control samples, as described previously [10], with a signifi-
cance level of P<0.05.
Statistical analysis
The data are expressed as mean±standard deviation (SD).
Student’s t-test was applied using Microsoft Office Excel
and a P value of less than 0.05 indicated a statistically signif-
icant difference.
RESULTS
NAC increases the in vitro replication of
C. pneumoniae
Initially, we wanted to check the potential anti-chlamydial
effect of NAC under in vitro conditions. During our experi-
ments, different concentrations of NAC were applied using
two approaches. First, a decreasing concentration of NAC
was mixed directly with C. pneumoniae, and the host cells
were immediately infected. Among the concentrations
applied, doses of 10mgml 1 and 2mgml 1 NAC were
toxic to the cells. Surprisingly, 0.1mgml 1 NAC resulted in
a nearly sixfold increase in the number of C. pneumoniae
inclusions in McCoy cells as compared to the number
observed after infection with untreated C. pneumoniae
(P<0.05; Fig. 1). Accordingly, we chose this concentration in
later studies. In the second approach, C. pneumoniae was
preincubated with NAC at the respective three concentra-
tions by shaking the mixture of C. pneumoniae and NAC
continuously for 1 h before infecting the cells. As shown in
Fig. 1, there was no significant difference in the infectivity
of C. pneumoniae pretreated for 1 h with NAC and C. pneu-
moniae treated with 0.1mgml 1 NAC immediately before
inoculation of the cells (P>0.05).
NAC increases the binding of C. pneumoniae to the
host cell
To investigate whether NAC is able to influence the attach-
ment of C. pneumoniae, McCoy and the more relevant
A549 epithelial cells of human respiratory origin were
infected with NAC-pretreated C. pneumoniae or with
untreated C. pneumoniae. As shown in Fig. 2(a, b, d), NAC-
treated C. pneumoniae produced a significantly higher
fluorescence intensity as compared to the untreated
C. pneumoniae in McCoy cells. A similar effect was
observed in the A549 cells (Fig. 2e, f, j). The control cells
did not display any fluorescence (Fig. 2c, g).
Subsequent experiments indicated that the removal of NAC
with the culture medium from C. pneumoniae did not sig-
nificantly modify the number of replicating C. pneumoniae
as compared to the outcome of the infection with unwashed
C. pneumoniae (P>0.05; Fig. 3). Adding NAC to the cells 6
or 24 h after C. pneumoniae infection did not change the
number of inclusions formed by C. pneumoniae (Fig. 3).
Furthermore, preincubation of the host cells with NAC for
48 h before infection with C. pneumoniae did not modify
the replication of C. pneumoniae (data not shown).
Exposure to NAC not only increases the chlamydial
lung burden, but also prolongs the infection in mice
Here, we investigated whether NAC might aggravate the
chlamydial infection in the short term. Twenty mice were
infected with C. pneumoniae, and 10 were treated with
10mg kg 1 NAC per os at the same concentration as that
applied for human respiratory infections as a mucolytic
drug for 6 days. On the seventh day, the mice were sacri-
ficed; the lungs were removed for the determination of
recoverable C. pneumoniae. We found that after 6 days of
Fig. 1. The effect of different concentrations of NAC and different
treatment conditions on C. pneumoniae replication. McCoy cells were
infected with C. pneumoniae treated with different concentrations
(0.01–1mgml 1) of NAC at the time of inoculation or infected with C.
pneumoniae pretreated with NAC. C. pneumoniae inclusions were
counted under a UV microscope after indirect immunofluorescence
staining. Here, the bars denote the means and SDs of the results on
five parallel tissue wells (*P<0.05).
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exposure to NAC the severity of the C. pneumoniae
infection increased. The number of recoverable chlamydial
inclusions was approximately three times higher in the
NAC-treated group than in the C. pneumoniae-infected
mice without NAC treatment (Fig. 4a). Next, we investi-
gated whether NAC prolongs the clearance of C. pneumo-
niae from the lungs. Sixteen mice were infected with
C. pneumoniae and eight mice were treated with NAC for
19 days. On the twentieth day, the mice were sacrificed
and their lungs were removed for the detection of viable
C. pneumoniae. All of the mice were C. pneumoniae cul-
ture-positive in the NAC-treated group and the number of
C. pneumoniae inclusions was 2.5 times higher than that
in the control group. Moreover, in the control group two
mice became culture-negative (the sensitivity of our
method was <40 i.f.u./lung), suggesting recovery from the
disease. The data for these mice were not included in
Fig. 4(b).
Ax does not increase the number of infective
C. pneumoniae
To look for a better alternative to NAC, the effect of Ax on
C. pneumoniae replication was tested in in vitro and in vivo
systems. Using concentrations of 0.002 and 0.01mgml 1,
Ax did not cause any significant changes in bacterial replica-
tion in McCoy cells, but 0.05mgml 1 Ax had a strong
antimicrobial effect and this reduced the number of
C. pneumoniae to approximately one-fifth of that observed
with untreated cells (P<0.05; Fig. 5a). As shown in Fig. 5(b),
none of the applied concentrations of Ax influenced host
cell viability. Increasing the dose to 0.25mgml 1 Ax proved
to be toxic to the cells (data not shown). We then wanted to
determine the reason for the antimicrobial activity of Ax.
An identical experiment to that performed with NAC was
conducted. Ax-treated and untreated C. pneumoniae were
inoculated into McCoy and A549 cells, and the cells were
stained using the immunofluorescence method. An increase
in immunofluorescence was not observed in this case, and
we inferred that the Ax treatment did not modify the num-
ber of C. pneumoniae EBs attached to the cell membrane
Fig. 2. The effect of NAC treatment on C. pneumoniae attachment. McCoy or A549 cells were infected with NAC-treated (0.1mgml 1)
(a, e) or untreated C. pneumoniae (Cpn) (b, f). After the incubation period, the cells were stained as described above in the Methods sec-
tion. Fluorescence signals were analysed via UV microscopy, and the immunofluorescence of non-infected, C. pneumoniae-infected or
drug-treated C. pneumoniae-infected cells was analysed quantitatively by ImageQuantTL 8.1 software. The results are expressed as
the mean±SD of the data from three independent experiments, *P<0.05 (d, j).
Fig. 3. The effect of pre- or post-infection exposure to NAC on C.
pneumoniae replication. The number of C. pneumoniae inclusions were
counted in McCoy cells infected with untreated C. pneumoniae (Cpn),
cells infected with C. pneumoniae preincubated for 1 h with (0.1mg
ml 1) NAC and subsequently washed via high-speed centrifugation
(Cpn+NAC washed), cells infected with NAC-treated but unwashed C.
pneumoniae (Cpn+NACunwashed) and cells infected with untreated C.
pneumoniae to which NAC was added 6 h (Cpn+NAC 6 h) or 24 h (Cpn
+NAC 24 h) post-infection. The C. pneumoniae inclusions were revealed
by indirect immunofluorescence days post-infection. The means of
the titres are expressed as i.f.u. ml 1 in five parallel cultures and the
SDs are shown.
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(data not shown). It is well documented that IDO1,2 shows
antimicrobial activity that metabolizes the tryptophan,
which is essential in chlamydial replication. We then tested
whether Ax might influence the expression of IDO1,2. Ax
caused a 2.5-fold increase in IDO2 expression in C. pneumo-
niae-infected cells as compared to the expression in
untreated cells. In our experiments, NAC treatment did not
influence the expression of IDO1,2 in C. pneumoniae-
infected cells (data not shown). To further investigate the
role of Ax during C. pneumoniae infection, our mice were
infected with C. pneumoniae and from the second day were
treated with tap water-diluted Ax at the same concentration
as is applied for human respiratory infections when it is
used as a mucolytic drug (1.25mg kg 1). The control mice
were given tap water. During the 7-day period, the behav-
iour (activity and appetite) and weight of the animals did
not change significantly between groups (data not shown).
The mice were sacrificed 7 days after the infection and the
number of recoverable C. pneumoniae was counted from
the lungs by direct immunofluorescence. As shown in Fig. 5
(c), the number of recoverable C. pneumoniae did not
change significantly in the Ax-treated and un-treated
C. pneumoniae-infected group of mice.
DISCUSSION
NAC is a multifaceted drug that is used in the treatment of
different diseases, mainly as a mucolytic agent. It is rela-
tively inexpensive and commercially available as an over-
the-counter (OTC) medicine. It has been shown to increase
the level of GSH, the body’s major antioxidant, by increas-
ing glutathione S-transferase activity. It is a powerful anti-
oxidant and has the potential to treat diseases characterized
by the generation of free oxygen radicals [1]. For instance,
NAC is a therapeutic option in chronic obstructive pulmo-
nary disease. In an open-label study of 1392 patients, NAC
reduced the viscosity of expectorated sputum, reduced
cough severity and improved the ease of expectoration in
patients after 2 months of treatment [11]. Furthermore,
NAC dramatically attenuated influenza symptoms in a
group of patients as compared with a placebo-treated
group [12].
The direct antimicrobial role of NAC is not well defined,
but there are data regarding its inhibitory effect on biofilm
formation. NAC displayed a direct antimicrobial effect
against extracellular pathogens, but the concentrations
applied by different authors varied greatly (0.003–80mg
ml 1) [13–15]. In the case of tuberculosis, NAC was found
to play a part in inhibiting the growth of intracellular Myco-
bacterium tuberculosis through bacteriostatic mechanisms
[16]. In our study, we found that instead of decreasing bac-
terial replication, NAC actually increased the number of
replicating C. pneumoniae in both in vitro and in vivo infec-
tions. Based on our in vitro experiment, we disclosed that
NAC increased the attachment of the pathogens to the host
cells (Fig. 2). Lazarev et al. investigated the role of intracel-
lular GSH in C. trachomatis infection, and they found that
the treatment of cells with buthionine sulfoximine, which
causes the irreversible inhibition of GSH biosynthesis or
hydrogen peroxide-induced oxidation of GSH, decreased
the number of C. trachomatis inclusions. In contrast with
this finding, the treatment of cells with NAC increased the
number of chlamydial inclusions. The researchers con-
cluded that GSH plays a crucial role in chlamydial replica-
tion. In their experiments NAC was used as a GSH
precursor, and they did not attempt to investigate the anti-
chlamydial effect of NAC [7]. However, it is well known
that the infectivity of Chlamydia species depends on the
reduced status of the cell membrane protein OmcB [5]. In
agreement with our hypothesis, NAC treatment of the EBs
increases the attachment directly, probably by reducing
OmcB, which could not have been from an increased level
of GSH, because NAC was removed from the culture
medium in some of our experiments. It would be worth
examining other reducing agents, such as ascorbic acid
(vitamin C), to find out whether they influence the binding
of C. pneumoniae EBs onto host cells.
Fig. 4. Recoverable i.f.u. in C. pneumoniae-infected mice with or without oral NAC treatment. The lung homogenates of infected (Cpn)
or infected and NAC-treated (10mg kg 1) (Cpn+NAC) mice on day 7 (a) or on day 20 (b) post-infection were inoculated onto McCoy cell
monolayers, and C. pneumoniae inclusions were detected by indirect immunofluorescence. Here, the data are the means±SD of the
number of C. pneumoniae inclusions (i.f.u./lung) in the lung homogenates of individual mice (*P<0.05).
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Fig. 5. The effect of Ax treatment on in vitro and in vivo C. pneumoniae infection. (a) McCoy cells were infected with C. pneumoniae
(2103 i.f.u.) and simultaneously treated with different amounts of Ax (0.002–0.05mgml 1). C. pneumoniae inclusions were detected by
indirect immunofluorescence. Here, the data are presented as the means±SD of the results in five parallel cultures. (b) The cell num-
bers for different concentrations of Ax. Five parallel wells of viable cells were counted under a light microscope using trypan blue dye.
(c) A group of 10 C. pneumoniae-infected mice were treated per os with Ax (1.25mg kg 1). The mice were sacrificed 7 days after infec-
tion and the number of infective C. pneumoniae was detected in the homogenized lungs by inoculation into McCoy cells and staining
using indirect immunofluorescence. The symbols (., C. pneumoniae-infected; ○, C. pneumoniae-infected+Ax-treated) stand for individual
mice. The bars represent the means of the recoverable C. pneumoniae inclusions in the groups.
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Aside from the negative effect of NAC on acute C. pneumo-
niae infection, we need to take into account another possible
effect of this drug. C. trachomatis, which belongs to the fam-
ily Chlamydiaceae, is one of the most common sexually
transmitted pathogens. Unfortunately, the infection is
asymptomatic in up to 70% of the cases. This means that
the infections usually go unrecognized. The severe conse-
quences of chronic C. trachomatis infection are ectopic
pregnancy, infertility, or a pelvic inflammatory disease [17].
In the worst-case scenario, NAC applied simultaneously in
the treatment of ongoing respiratory diseases may not only
increase the growth of C. pneumoniae, but stimulate the
growth of C. trachomatis as well.
In order to circumvent NAC’s aggravating effect on
C. pneumoniae infection, we looked for a better mucolytic
agent that does not increase the severity of the respiratory
disease. In our in vitro study, Ax displayed significant anti-
chlamydial activity that was not associated with decreased
binding of the pathogen to the host cells. The complete
antimicrobial mechanism of Ax was not analysed, but Ax
treatment increased the expression of the anti-chlamydial
IDO2, which may in part cause a reduction in the number
of pathogens. In our in vivo experiment, mice were
infected with C. pneumoniae and then treated with Ax.
Using a human equivalent Ax/body weight dose we found
no significant difference in the number of recoverable
C. pneumoniae between the treated and the untreated
groups. The limitation of our study is that despite the
promising in vitro results, we did not check to see whether
a higher dose of Ax has an anti-chlamydial effect in vivo.
Yang et al. found that 10mg kg 1 day 1 (which is eight
times higher than the normal dose in a human) signifi-
cantly reduced the mortality of mice infected with a lethal
dose of H3N2 influenza virus [18]. Further experiments
are needed to investigate the possible anti-chlamydial
effects of Ax at a higher dose.
In Germany, NAC is the second most popular drug for
acute coughs, with 23.5% of the OTC expectorant market
share in 2015 (Ax is first with 24%) [19]. C. pneumoniae is
a common respiratory pathogen and unfortunately it is not
always diagnosed correctly, and if a doctor suggests NAC as
a mucolytic agent it might worsen and delay the patient’s
recovery. Based on the prevalence of C. pneumoniae, many
patients could suffer prolonged respiratory disease because
of NAC.
Overall, on the basis of our results, we can state that NAC
can aggravate and prolong the infection caused by C. pneu-
moniae in an animal model. This information will be use-
ful for physicians who recommend NAC as a mucolytic
drug in respiratory diseases with a non-identified aetiology.
In the case of a C. pneumoniae infection, a correct labora-
tory diagnosis is imperative, because in its absence the use
of NAC may worsen the patient’s chance of recovery. It is
important that clinical studies to prove our results are
implemented. Instead of NAC, Ax might be recommended,
as it does not support the growth of C. pneumoniae in the
mouse model.
Funding information
This work was supported by GINOP-2.3.2-15-2016-00012 and Human
Resources Development Operational Program EFOP-3.6.1-16-2016-
00008.
Acknowledgements
We would like to thank Györgyi Müllerne Deak for her excellent techni-
cal support. We also thank the anonymous blogger who inspired our
experiments. He had pneumonia caused by C. pneumoniae and com-
plained about his worsening status after taking NAC prescribed by a
physician.
Conflicts of interest
The authors declare that there are no conflicts of interest.
Ethical statement
The experiments were approved by the Animal Welfare Committee of
the University of Szeged and they conformed to Directive 2010/63/EU
of the European Parliament.
References
1. Mokhtari V, Afsharian P, Shahhoseini M, Kalantar SM, Moini A. A
review on various uses of N-acetyl cysteine. Cell J 2017;19:11–17.
2. Beeh KM, Beier J, Esperester A, Paul LD. Antiinflammatory prop-
erties of ambroxol. Eur J Med Res 2008;13:557–562.
3. Stetinova V, Herout V, Kvetina J. In vitro and in vivo antioxidant
activity of ambroxol. Clin Exp Med 2004;4:152–158.
4. Choroszy-Król I, Frej-Ma¸ drzak M, Hober M, Sarowska J, Jama-
Kmiecik A. Infections caused by Chlamydophila pneumoniae. Adv
Clin Exp Med Off Organ Wroclaw Med Univ 2014;23:123–126.
5. Abromaitis S, Stephens RS. Attachment and entry of Chlamydia
have distinct requirements for host protein disulfide isomerase.
PLoS Pathog 2009;5:e1000357.
6. Moelleken K, Hegemann JH. The Chlamydia outer membrane pro-
tein OmcB is required for adhesion and exhibits biovar-specific
differences in glycosaminoglycan binding. Mol Microbiol 2008;67:
403–419.
7. Lazarev VN, Borisenko GG, Shkarupeta MM, Demina IA,
Serebryakova MV et al. The role of intracellular glutathione in the
progression of Chlamydia trachomatis infection. Free Radic Biol
Med 2010;49:1947–1955.
8. Burian K, Hegyesi H, Buzas E, Endresz V, Kis Z et al. Chlamydo-
phila (Chlamydia) pneumoniae induces histidine decarboxylase pro-
duction in the mouse lung. Immunol Lett 2003;89:229–236.
9. Caldwell HD, Kromhout J, Schachter J. Purification and partial
characterization of the major outer membrane protein of Chla-
mydia trachomatis. Infect Immun 1981;31:1161–1176.
10. Yuan JS, Reed A, Chen F, Stewart CN. Statistical analysis of real-
time PCR data. BMC Bioinformatics 2006;7:85.
11. Tattersall AB, Bridgman KM, Huitson A. Acetylcysteine (Fabrol) in
chronic bronchitis–a study in general practice. J Int Med Res 1983;
11:279–284.
12. de Flora S, Grassi C, Carati L. Attenuation of influenza-like symp-
tomatology and improvement of cell-mediated immunity with long-
term N-acetylcysteine treatment. Eur Respir J 1997;10:1535–1541.
13. Aslam S, Trautner BW, Ramanathan V, Darouiche RO. Combina-
tion of tigecycline and N-acetylcysteine reduces biofilm-embedded
bacteria on vascular catheters. Antimicrob Agents Chemother
2007;51:1556–1558.
14. Zhao T, Liu Y. N-acetylcysteine inhibit biofilms produced by
Pseudomonas aeruginosa. BMC Microbiol 2010;10:140.
15. Olofsson AC, Hermansson M, Elwing H. N-acetyl-L-cysteine
affects growth, extracellular polysaccharide production, and bac-
terial biofilm formation on solid surfaces. Appl Environ Microbiol
2003;69:4814–4822.
Kókai et al., Journal of Medical Microbiology
7
16. Allen M, Bailey C, Cahatol I, Dodge L, Yim J et al. Mechanisms of
control of Mycobacterium tuberculosis by NK cells: role of gluta-
thione. Front Immunol 2015;6:508.
17. Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F et al. Risk of
sequelae after Chlamydia trachomatis genital infection in women.
J Infect Dis 2010;201:134–155.
18. Yang B, Yao DF, Ohuchi M, Ide M, Yano M et al. Ambroxol
suppresses influenza-virus proliferation in the mouse airway
by increasing antiviral factor levels. Eur Respir J 2002;19:952–
958.
19. Morice A, Kardos P. Comprehensive evidence-based review on
European antitussives. BMJ Open Respir Res 2016;3:e000137.
Kókai et al., Journal of Medical Microbiology
8
Five reasons to publish your next article with a Microbiology Society journal
1. The Microbiology Society is a not-for-profit organization.
2. We offer fast and rigorous peer review – average time to first decision is 4–6 weeks.
3. Our journals have a global readership with subscriptions held in research institutions around
the world.
4. 80% of our authors rate our submission process as ‘excellent’ or ‘very good’.
5. Your article will be published on an interactive journal platform with advanced metrics.
Find out more and submit your article at microbiologyresearch.org.
